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Eﬀ ect of HIV on survival in patients with non-small-cell 
lung cancer in the era of highly active antiretroviral therapy: 
a population-based study
Ramesh Rengan, Nandita Mitra, Kaijun Liao, Katrina Armstrong, Anil Vachani
Summary
Background HIV-infected patients with lung cancer have been reported to have poorer survival than uninfected 
patients. Whether this outcome holds true in the era of highly active antiretroviral therapy (HAART) is unclear. We 
examined the eﬀ ect of HIV infection on clinical outcome in patients with lung cancer who are also receiving HAART.
Methods Patients diagnosed with non-small-cell lung cancer (NSCLC) from Jan 1, 2000, to Dec 31, 2005, with or 
without HIV infection were identiﬁ ed by querying the Surveillance, Epidemiology, and End Results registry and the 
Medicare lung cancer database. Survival analysis by stage and treatment delivered comparing the HIV-infected 
patients with uninfected controls was done with Kaplan-Meier and Cox models with propensity score adjustments.
Findings 71 976 patients with NSCLC were identiﬁ ed as uninfected controls and 322 patients with NSCLC were 
identiﬁ ed in the HIV group; median age was 75 years for both groups. Median overall survival for all stages was 
7·0 months (95% CI 7·0–7·0) for uninfected controls versus 8·0 months (6·0–10·0) for the HIV group (p=0·16); for 
those with stage I/II disease it was 37·0 months (36·0–39·0) versus 43·0 months (26·0–58·0; p=0·37); for those with 
stage IIIA/IIIB disease it was 7·0 months (7·0–7·0) versus 3·0 months (2·0–8·0; p=0·051); and for those with stage 
IV disease it was 3·0 months for both groups (95% CI 3·0–3·0 for controls; 2·0–5·0 for HIV group; p=0·77). After 
propensity score adjustment, the survival diﬀ erence in stage IIIA/IIIB was no longer seen (hazard ratio 0·88; 95% CI 
0·71–1·09). The median survival for HIV infected patients with stage I or II NSCLC who underwent surgical resection 
was 58·0 months (95% CI 57·0–60·0) for uninfected controls versus 50·0 months (42·0 to unestimable) for the HIV 
group (p=0·88).
Interpretation We noted no signiﬁ cant diﬀ erence in clinical outcome between patients with HIV and uninfected 
controls with NSCLC. Survival after curative surgical resection in early-stage patients was similar in HIV-infected 
individuals and uninfected controls. These data suggest that HIV status should not aﬀ ect therapeutic decision making 
in NSCLC.
Funding US National Cancer Institute (award number UC2CA148310).
Introduction
Lung cancer is the leading cause of cancer-related mor-
tality in the USA, accounting for around 170 000 deaths 
in 2010.1 Non-small-cell lung cancer (NSCLC) accounts 
for roughly 85% of all lung cancers.2 The standard 
therapeutic approach for patients with stage I or stage II 
NSCLC is complete surgical resection.3 For patients 
with locally advanced NSCLC (stage IIIA or IIIB) 
disease, the current standard of care is concurrent 
chemoradiation.4 For patients with stage IV NSCLC, the 
standard treat ment consists of systemic chemotherapy 
alone with a cisplatin-based regimen.5–7 As a group, 
these treatments have modest eﬃ  cacy at the expense of 
substantial toxicity to the patient, with an expected 
median survival across all stages of lung cancer of 
15 months from the date of diagnosis.1 Because of 
concerns about toxicity, many of the clinical trials that 
have established the standards of care have explicitly 
excluded patients with signiﬁ cant comorbidities, 
including HIV infection, because of con cerns of 
inability to tolerate therapy.4,8,9
Immunosuppression leads to an increased risk for 
malignancy, as evidenced by increased incidence of 
unrelated cancers in transplant patients undergoing 
immunosuppressive therapy to prevent transplant re-
jection.10 Furthermore, immunosuppression associated 
with HIV infection has been established as a risk 
factor for various malignancies, including non-Hodgkin 
lymphoma, Kaposi’s sarcoma, Merkel cell carcinoma, 
cervical cancer, and lung cancer.11–14 Comparative studies 
have shown that the pattern of increased cancers in HIV 
patients was similar to that seen in immunosuppressed 
transplant patients, and that the risk correlates with 
CD4+ T-lymphocyte count, suggesting that immuno-
deﬁ ciency is probably the underlying cause of increased 
malignancy.15 Importantly, the risk of lung cancer in HIV-
infected patients is increased even after accounting for 
tobacco use.16
Findings from retrospective studies suggest that HIV-
infected patients with lung cancer have poorer clinical 
outcome and overall survival than uninfected patients.17,18 
Further, there are data to suggest a correlation between 
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lower CD4 count and poorer survival in HIV-infected 
patients with lung cancer.19,20 Although these ﬁ ndings 
suggest that lung cancer has a more aggressive pheno-
type in HIV-infected patients, these studies grouped 
patients with NSCLC and small-cell lung cancer (SCLC) 
together, did not account for the stage at diagnosis, and 
included a high number of patients from the pre-highly 
active antiretroviral therapy (HAART) era. Since the 
adoption of HAART in the mid-1990s, the expected 
survival of patients with HIV has improved sub-
stantially.21,22 Although HAART eﬀ ectively treats the 
immunosuppression associated with HIV infection, 
data also suggest that these drugs could diminish the 
eﬃ  cacy of the antineoplastic regimens routinely used in 
the treatment of lung cancer.23 Therefore, the clinical 
outcome of HIV-infected patients with lung cancer in the 
era of HAART remains unclear.
Our study was designed to assess overall survival in 
HIV-infected patients with NSCLC in the era of HAART 
compared with uninfected patients. Additionally, for 
patients with early stage NSCLC, for whom surgical 
resection is the standard of care, we have assessed overall 
survival in HIV-infected patients after surgical resection 
as compared with uninfected patients. Our goal was to 
establish whether NSCLC displayed a more aggressive 
phenotype in HIV-infected individuals, to quantify the 
eﬀ ect of viral infection on clinical outcome in patients 
with NSCLC. The broader objective was to establish the 
role that HIV infection should have in clinical decision 
making in patients with NSCLC.
Methods
Study design
The SEER-Medicare database is the result of a linkage 
of two population-based data sources: the Surveillance, 
Epidemiology and End Results (SEER) registry, spon-
sored by the US National Cancer Institute (NCI), and 
Medicare, a federally funded US programme that 
pro vides health insurance for people of age 65 years and 
over, disabled, or have end-stage renal disease. SEER 
captures clinical, demographic, treatment, and outcome 
data for cancer patients in speciﬁ c geographical locations, 
representing 28% of the US population. The linkage to 
Medicare provides longitudinal data for all claims from 
the Center for Medicare and Medicaid Services from the 
time of eligibility to death.24,25 Patients younger than 
65 years are excluded from this registry unless they are 
disabled or have end-stage renal disease.
This study was approved by the institutional review 
board of the University of Pennsylvania.
Study population
We developed an analytic dataset from the SEER-
Medicare linked database, consisting of patients with a 
diagnosis of lung cancer (ICD-9 code 162·XX) and non-
small-cell histology (adenocarcinoma, squamous cell 
carcinoma, large cell, bronchoalveolar carcinoma, or 
NSCLC not otherwise speciﬁ ed) contained in the SEER 
registry who were diagnosed between Jan 1, 2000, and 
Dec 31, 2005. Patients who were enrolled in Medicare, 
but receive their beneﬁ ts through a third party, such as 
a health maintenance organisation, or private fee-for-
service plan, were excluded from this analysis because of 
incomplete claims data in Medicare for these patients. 
Additionally, patients who are not enrolled both in 
Medicare part A (hospital services) and part B (physician 
and outpatient services) were excluded. This analysis was 
restricted to this period to examine patients in the era of 
HAART, which became standard of care in the mid-1990s 
in the USA9,22 and current staging frame works, including 
the use of FDG-PET, for NSCLC to minimise the eﬀ ect of 
stage migration.26 HIV-infected patients in the SEER-
Medicare registry were identiﬁ ed by one of two HIV 
ICD-9 diagnosis codes (V08 and 042).
Statistical analysis
We compared baseline patient and disease characteristics 
between HIV-infected and control patients with χ² tests. 
Overall survival was deﬁ ned as the interval from the date 
of diagnosis to the date of death as provided by Medicare. 
Patients still alive at the end of follow-up were considered 
to be censored on Dec 31, 2007. We compared overall 
survival for the HIV-infected group versus the control 
group with the Kaplan-Meier approach and the log-rank 
statistic. Survival comparisons were also done after 
stratiﬁ cation for disease stage.
We used propensity score methods to account for 
imbalances between the two comparison groups on 
measured covariates.27,28 We chose propensity score 
adjustment in our Cox model rather than traditional 
covariate adjustment, since recent ﬁ ndings have sug-
gested that this method is advantageous when analysing 
large observational datasets such as SEER-Medicare.29 
Our group has previously used this method to examine 
SEER-Medicare data.30,31 In an observational study such 
For more on SEER see 
http://seer.cancer.gov/
HIV+ 
(n=322)
% Control 
(n=71 976)
% χ² p value
Stage I/II 114 35·40% 20 016 27·81% 0·002
Stage IIIA/IIIB 96 29·81% 22 793 31·67% 0·48
Stage IV 112 34·78% 29 167 40·50% 0·04
Median age (IQR) 75 (69–81) 75 (69–81) 0·99
Race
White 231 71·74% 62 859 87·33% <0·0001
African American 76 23·60% 6056 8·41% <0·0001
Other 15 4·66% 3061 4·25% 0·72
Comorbidities
0 16 4·97% 6164 8·56% 0·02
1 28 8·70% 11 660 16·20% 0·0003
2 or more 278 86·34% 54 152 75·24% <0·0001
Median income in bottom two 
quartiles (range in US dollars)
139 43·17 
(7–32 492)
33 117 46·01 
(7–32 492)
0·65
Table: Patient characteristics
Articles
www.thelancet.com/oncology   Vol 13   December 2012 1205
as this one, covariate imbalances could potentially lead to 
biased survival estimates due to confounding. We 
calculated propensity scores using multivariable logistic 
regression with HIV infection as the outcome of interest, 
with adjustment for race, median income, stage, sex, and 
comorbidities. We used Cochran-Mantel-Haenszel tests 
to establish whether these covariates were balanced 
within propensity score quintiles, and found that all 
covariates were balanced. We then used multivariable 
Cox proportional hazards models to compare death from 
any cause between the HIV-infected and control groups 
after adjustment for the propensity score as a continuous 
variable. To assess the proportional hazards assumption, 
we used the Schoenfeld residuals test and complementary 
log-log plots.
The Kaplan-Meier method was used to compare 
patients with stage I and II disease with or without HIV 
infection who underwent deﬁ nitive surgical resection to 
assess the eﬀ ect of HIV infection in patients undergoing 
deﬁ nitive surgical resection for treatment of early stage 
NSCLC. All statistical analyses were done with the 
Statistical Analysis System (SAS) version 9.3.
Role of the funding source
The sponsor did not have any role in study design, 
collection, analysis, or interpretation of the data, or in 
writing of this report. RR, KL, NM, KA, and AV had 
access to the raw data contained in this report. The 
corresponding author had full access to all of the data 
and the ﬁ nal responsibility to submit for publication.
Results
322 patients were identiﬁ ed from Jan 1, 2000, to 
Dec 31, 2005, with a diagnosis of HIV (HIV group) and 
71 976 individuals with a diagnosis of NSCLC were 
identiﬁ ed who were not associated with a diagnosis of 
HIV (control group). A similar proportion of patients 
were stage IIIA/IIIB and stage IV in both groups, but 
there was a signiﬁ cantly greater proportion of patients 
with stage I/II disease in the HIV-infected group than the 
control group (p=0·002, table). There was a signiﬁ cant 
diﬀ erence in ethnic background between the two groups, 
with the HIV-infected group containing a higher pro-
portion of African Americans (23·6% vs 8·4%, p<0·0001). 
The proportion of patients with their median income in 
HIV-infected
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Figure 1: Kaplan-Meier comparative survival of HIV-infected and uninfected control NSCLC patients: (A) all stages; (B) stage I/II; (C) stage IIIA/IIIB; and (D) stage IV
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the bottom two quartiles was much the same between 
the two groups (table). 
The unadjusted median survival for uninfected control 
patients with NSCLC was 7·0 months (95% CI 7·0–7·0) 
com pared with 8·0 months (6·0–10·0) for the HIV group 
(p=0·16). When stratiﬁ ed by stage, the unadjusted 
median survival for stage I/II patients was 37·0 months 
(95% CI 36·0–39·0) for uninfected controls compared 
with 43·0 months (26·0–58·0) for the HIV group 
(p=0·37), for those with stage IIIA/IIIB disease, it was 
7·0 months (7·0–7·0) for uninfected controls compared 
with 3·0 months (2·0–8·0) for the HIV group (p=0·051), 
and for those with stage IV disease, it was 3·0 months 
(3·0–3·0 for control group and 2·0–5·0 for HIV group) 
for un infected controls and the HIV group (p=0·77; 
ﬁ gure 1). After using propensity score adjustment to 
account for potential confounders, there remained no 
diﬀ erence in survival between uninfected controls and 
the HIV group across all stages (hazard ratio 1·03, 95% CI 
0·91–1·17), stage I/II (1·22, 0·93–1·6), stage IIIA/IIIB 
(0·88, 0·71–1·09), and stage IV (0·99, 0·82–1·21).
To examine the eﬀ ect of treatment on survival, 
we restricted our analysis to stage I and II patients 
undergoing deﬁ nitive surgical resection alone, which is 
the standard of care.32 Of the 114 HIV-infected patients 
with stage I or II disease, 92 (80·7%) underwent surgical 
resection. Of the 20 016 patients in the control group with 
stage I or II disease, 13 640 (68·1%) underwent surgical 
resection. The median survival for HIV-infected patients 
with stage I or II NSCLC undergoing surgical resection 
was 50·0 months (95% CI 42·0 to unestimable) versus 
58·0 months (57·0–60·0) for resected patients with 
stage I/II disease in the control group (p=0·88; ﬁ gure 2). 
The 5-year survival was 47% for HIV-infected patients 
undergoing surgical resection versus 49% for the control 
group (p=0·88).
Discussion
Our results indicate that, across all stages, survival 
outcomes in HIV-infected patients with NSCLC are not 
signiﬁ cantly diﬀ erent from uninfected patients. Further, 
when survival within stage subgroups was compared 
between HIV-infected patients with NSCLC and unin-
fected patients, no signiﬁ cant diﬀ erence was identiﬁ ed. 
HIV-infected patients with stage IIIA/IIIB disease 
seemed to have poorer survival on unadjusted analysis, 
but this ﬁ nding was not signiﬁ cant. After adjustment for 
imbalances in the covariate distributions between the 
groups, there was clearly no association with HIV status 
and poorer survival. Additionally, when assessing 
stage I/II patients undergoing deﬁ nitive sur gical 
resection, survival was not signiﬁ cantly diﬀ erent in HIV-
infected patients undergoing surgery com pared with 
uninfected patients. Taken together, these data suggest 
that NSCLC does not display a more aggressive 
phenotype in HIV-infected patients.
Our ﬁ ndings are in contrast to previously published 
reports that suggest that HIV-infected patients with lung 
cancer fare worse when compared with uninfected 
patients (panel).17,18 Notably, these previous studies 
included patients from the pre-HAART era and spanned 
over three decades to identify adequate patient numbers. 
These studies did not distinguish between NSCLC and 
SCLC, which have signiﬁ cantly diﬀ erent treatments and 
expected survival and as such cannot be grouped together 
for the purpose of examination of clinical outcome.1,2,33 A 
retrospective study by Brock and colleagues18 examined 
the eﬀ ect of HIV infection across diﬀ erent stage 
subgroups in a combined cohort of SCLC and NSCLC 
and pre-HAART and post-HAART patients. Although 
the authors did not note any signiﬁ cant diﬀ erence in 
stage-speciﬁ c survival, the overall survival of HIV-
infected patients with lung cancer was worse than HIV-
indeterminate patients. Their results may be due, in part, 
to the increased proportion of advanced stage patients 
(III and IV) seen in the HIV-infected group relative to the 
HIV-indeterminate patients.18 In a report from the Italian 
Cooperative Group on AIDS and Tumors, Spina and 
colleagues reported signiﬁ cantly poorer survival in 
39 patients with HIV and lung cancer treated in the pre-
HAART era (1986–97) than in matched controls (median 
survival of 5·0 vs 10·0 months; p<0·0001).34,35 A follow-up 
study36 com pared survival in HIV-infected patients with 
lung cancer from the pre-HAART era to the HAART era, 
demonstrating a signiﬁ cant improvement in survival 
(from 3·8 to 7·0 months; p=0·01). The ﬁ ndings of that 
study sug gested that HIV infection could have been an 
adverse prognostic factor in the pre-HAART era, but that 
this eﬀ ect has diminished in the era of HAART.36
Survival in NSCLC is heavily dependent on stage at 
presentation, with 5-year survival ranging from 80% for 
stage I disease to less than 1% in stage IV disease.1 
Medicare-approved reimbursement of PET for staging 
of NSCLC in 1998, leading to rapid adoption of this 
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Figure 2: Kaplan-Meier comparative survival of HIV-infected and uninfected control patients with stage I/II 
NSCLC after surgical resection
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modality.37 This shift in staging has led to a signiﬁ cant 
improvement in stage-speciﬁ c survival in NSCLC from 
the late 1990s to the early 2000s.38 To minimise the 
potential eﬀ ect of this confounder and to restrict our 
analysis to the current era of HAART we did not include 
any patients before 2000 in this study and only examined 
the period from Jan 1, 2000, to Dec 31, 2005.
People with HIV often have inadequate access to 
medical care compared with the general population, 
which can often result in a delay in diagnosis, more 
advanced stage at initial presentation, and suboptimum 
delivery of treatment.18,39 In our study, we found that HIV-
infected patients with lung cancer had more early stage 
disease than did those in the uninfected control group. 
Although the exact reason for our observation is unclear, 
HIV-infected patients might have received regular 
medical care while on HAART and therefore were 
diagnosed at an earlier stage.
Since the introduction of HAART in 1996, mortality 
from HIV/AIDS has decreased substantially. In a study 
of survival in HIV-infected patients in Denmark, Lohse 
and colleagues21 reported that mortality rate de creased 
by 62% with the introduction of HAART. They further 
reported that this translated into an improvement in 
median survival of an HIV-infected patient in the 
HAART era to 32·5 years from 7·6 years in the pre-
HAART era.21 By contrast, the median survival of a 
patient with lung cancer across all stages is around 
15 months.1 An analysis by Persad and colleagues 
showed that 25% of all clinical trials for patients with 
NSCLC and 29% of clinical trials for patients with 
SCLC explicitly excluded patients with HIV.9 Given the 
signiﬁ cant improvement in survival with HIV in the 
HAART era, Persad and coworkers argued for greater 
inclusion of patients with HIV in clinical trials across 
all cancers.
There are several limitations to our analysis. Although 
this study represents the largest study, to our knowledge, 
to date on the eﬀ ect of HIV on clinical outcome in 
NSCLC, the number of HIV-infected patients identiﬁ ed 
is fairly small, leading to limited power to detect a small 
survival diﬀ erence. Although there are data for the 
incidence of NSCLC in patients with HIV,16 there are 
limited data for the incidence of HIV in patients with 
NSCLC, with reports ranging from 50 to 1800 HIV-
infected individuals per 100 000 patients with lung 
cancer.17,18 Our data is concordant with these reports. 
Additionally, SEER-Medicare does not capture 
information on the use of HAART. Although we 
restricted our analysis to patients treated between Jan 1, 
2000, and Dec 31, 2005, when most HIV patients should 
have been receiving HAART, we could not conﬁ rm that 
the patients included in our analysis were being treated 
with HAART. A recent report assessing US trends in 
HAART use showed widespread adoption of treatment 
during this period, with around 80% of HIV-infected 
patients on antiretroviral therapy.40 SEER-Medicare 
also does not capture information on antineoplastic 
adminis tration. HAART regimens have previously been 
shown to interfere with the antineoplastic regimens that 
are routinely used in the treatment of lung cancer.23 The 
extent to which this interaction aﬀ ected the results seen 
in our study is unclear. The potential for drug–drug 
interactions must be taken into account when admin-
istering antineoplastic agents in patients with HIV/AIDS 
on HAART.41 Also, SEER-Medicare does not capture CD4 
count data, a factor which has previously reported to 
correlate with survival in HIV-infected patients with lung 
cancer.19 SEER-Medicare does not capture in formation 
on the incidence of opportunistic infections or the 
administration of prophylactic regimens and therefore 
this is not included in this analysis. Add itionally, SEER-
Medicare does not capture cause of death and therefore 
death cannot unambiguously be attributed to lung cancer 
in our study. Competing risks of death in HIV-infected 
patients with NSCLC from opportunistic infec tions or 
complications from antineoplastic therapy, such as 
neutropenia, could not be quantiﬁ ed in our analysis. 
Although our analysis accounted for measured 
confounders, the results could be biased because of the 
presence of unmeasured confounders, such as patient’s 
functional status at baseline. However, on the basis of 
our results, such an unmeasured confounder would have 
to be signiﬁ cantly imbalanced between the two 
Panel: Research in context
Systematic review
At the time that this study was designed, an increased 
incidence of NSCLC in HIV-infected patients had been 
reported. However, the clinical phenotype of NSCLC in the 
HIV-infected patient with lung cancer in the era of HAART was 
unclear. Before initiating our study, we searched the medical 
literature for comparative studies examining clinical outcome 
in HIV-infected lung cancer or HIV-infected patients with 
NSCLC when compared with HIV-uninfected or indeterminate 
patients with lung cancer. We searched PubMed (without any 
date or language restrictions) using the following terms: “HIV” 
and “survival” and “lung cancer”, or “HIV” and “survival” and 
“non-small cell lung cancer” or “HIV” and “lung cancer” or 
“HIV” and “non-small cell lung cancer” and repeated these 
searches including the term “antiretroviral therapy, highly 
active”. We identiﬁ ed studies that had retrospectively 
examined the outcome of HIV-infected patients with lung 
cancer and reported this group to have poorer survival when 
compared to uninfected or HIV-indeterminate patients with 
lung cancer or historical benchmarks for survival.
Interpretation
Our data suggest that survival of HIV-infected patients with 
NSCLC in the era of HAART is comparable to HIV-uninfected 
patients with NSCLC. These data suggest that HIV infection 
alone should not inﬂ uence treatment decision making when 
approaching the patient with NSCLC.
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comparison groups for the HIV group to show 
signiﬁ cantly poorer survival than the uninfected con-
trols.42 Additionally, because the data in SEER-Medicare is 
mainly composed of people older than 65 years, we were 
unable to examine the eﬀ ect of HIV infection on survival 
in younger patients.1 Notably, the median age of patients 
with HIV and lung cancer is generally reported to be 
younger than the average age of the lung cancer 
population.34,39,43 The clinical phenotype of lung cancer in 
younger patients with HIV could be distinct from that 
seen in patients over age 65 years. Age has been shown 
to be an important prognostic factor for survival in lung 
can cer, with older patients faring more poorly.44 Advanced 
age has also been shown to be an independent predictor 
of poor survival in HIV-infected patients initiating 
HAART.45 However, since SEER-Medicare does not 
capture data for patients under the age of 65 years, 
whether the results reported in our trial are applicable to 
all HIV-infected patients with lung cancer is unclear.
In conclusion, these data suggest that HIV infection 
alone in the era of HAART should not play a role in 
clinical decision making in treatment of patients with 
NSCLC. These data also add further support to the 
inclusion of HIV-infected patients in lung cancer 
clinical trials, where they are currently under-
represented. Notably, the Intergroupe Francophone de 
Cancerologie Thoracique has recently initiated a phase 
2, multicentre prospective study evaluating the 
combination of pemetrexed plus carboplatin in HIV-
positive patients with lung cancer and accrual to 
this trial is ongoing (ClinicalTrials.gov, number 
NCT01296113). Additionally, these data suggest that 
improving access to modern diagnostic imaging and 
cancer therapies are likely to signiﬁ cantly beneﬁ t 
patients with NSCLC with HIV since their outcome is 
similar to that of uninfected controls when treated with 
deﬁ nitive surgical resection. The clinical management 
of the HIV-infected patient with NSCLC, as with all 
patients with lung cancer, requires a multidisciplinary 
approach to individualise and optimise therapy and to 
manage toxicities.
Contributors
RR, NM, KL, and AV were responsible for the study concept and design. 
KL and AV acquired the data. RR, NM, KL, and AV were responsible for 
analysis and interpretation of data. RR, NM, and AV drafted the 
manuscript. RR, NM, KL, KA, and AV did critical revision of the 
manuscript for important intellectual content. NM and KL did the 
statistical analysis. KA and AV obtained funding. KA and AV provided 
administrative, technical, and material support. RR, NM, KL, KA, and AV 
supervised the study.
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest. 
Acknowledgments
This project was supported by award number UC2CA148310 from the NCI. The 
content is solely the responsibility of the authors and does not necessarily 
represent the oﬃ  cial views of the NCI or the National Institutes of Health. 
References
 1 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. 
CA Cancer J Clin 2010; 60: 277–300.
 2 Govindan R, Page N, Morgensztern D, et al. Changing 
epidemiology of small-cell lung cancer in the United States over the 
last 30 years: analysis of the surveillance, epidemiologic, and end 
results database. J Clin Oncol 2006; 24: 4539–44.
 3 Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus 
limited resection for T1 N0 non-small cell lung cancer. Lung Cancer 
Study Group. Ann Thorac Surg 1995; 60: 615–22.
 4 Curran W, Paulus R, Langer CJ, et al. Sequential vs concurrent 
chemoradiation for stage III non-small cell lung cancer (NSCLC): 
randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 
103: 1452–60.
 5 Schiller JH, Harrington D, Belani CP, et al. Comparison of four 
chemotherapy regimens for advanced non-small-cell lung cancer. 
N Engl J Med 2002; 346: 92–98.
 6 Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical 
Oncology Clinical Practice Guideline update on chemotherapy for 
stage IV non-small-cell lung cancer. J Clin Oncol 2009; 
27: 6251–66.
 7 Postmus PE, Scagliotti G, Groen HJM, et al. Standard versus 
alternating non-cross-resistant chemotherapy in extensive small cell 
lung cancer: an EORTC phase III trial. Eur J Cancer 1996; 
32A: 1498–503.
 8 Bradley J, Schild S, Bogart J, et al. RTOG 0617: a randomized phase 
iii comparison of standard-dose (60 Gy) versus high-dose (74 Gy) 
conformal radiotherapy with concurrent and consolidation 
carboplatin/paclitaxel +/- cetuximab in patients with stage IIIA/IIIB 
non-small cell lung cancer. Annual Proceedings of the ASTRO 
Annual Meeting, 2011. Abstract number LB2.
 9 Persad GC, Little RF, Grady C. Including persons with HIV 
infection in cancer clinical trials. J Clin Oncol 2008; 26: 1027–32.
 10 Engels EA, Pfeiﬀ er RM, Fraumeni JF Jr, et al. Spectrum of cancer 
risk among US solid organ transplant recipients. JAMA 2011; 
306: 1891–901.
 11 Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell 
carcinoma and HIV infection. Lancet 2002; 359: 497–98.
 12 Biggar RJ, Kirby KA, Atkinson J, McNeel TS, Engels E. Cancer risk 
in elderly persons with HIV/AIDS. J Acquir Immune Deﬁ c Syndr 
2004; 36: 861–68.
 13 Biggar RJ, Jaﬀ e ES, Goedert JJ, Chaturvedi A, Pfeiﬀ er R, Engels EA. 
Hodgkin lymphoma and immunodeﬁ ciency in persons with HIV/
AIDS. Blood 2006; 108: 3786–91.
 14 Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer 
with AIDS-related immunosuppression in adults. JAMA 2001; 
285: 1736–45.
 15 Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of 
cancers in people with HIV/AIDS compared with 
immunosuppressed transplant recipients: a meta-analysis. Lancet 
2007; 370: 59–67.
 16 Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. 
Elevated incidence of lung cancer among HIV-infected individuals. 
J Clin Oncol 2006; 24: 1383–88.
 17 Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in 
persons with AIDS. J Acquir Immune Deﬁ c Syndr 2005; 39: 293–99.
 18 Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and 
elevated mortality in an urban population with HIV and lung 
cancer: implications for patient care. J Acquir Immune Deﬁ c Syndr 
2006; 43: 47–55.
 19 Makinson A, Tenon JC, Eymard-Duvernay S, et al. Human 
immunodeﬁ ciency virus infection and non-small cell lung cancer: 
survival and toxicity of antineoplastic chemotherapy in a cohort 
study. J Thorac Oncol 2011; 6: 1022–29.
 20 Pakkala S, Chen Z, Rimland D, et al. Human immunodeﬁ ciency 
virus-associated lung cancer in the era of highly active antiretroviral 
therapy. Cancer 2012; 118: 164–72.
 21 Lohse N, Hansen AB, Gerstoft J, Obel N. Improved survival in 
HIV-infected persons: consequences and perspectives. 
J Antimicrob Chemother 2007; 60: 461–63.
 22 Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with 
and without HIV infection in Denmark, 1995–2005. Ann Intern Med 
2007; 146: 87–95.
 23 Makinson A, Pujol JL, Le Moing V, Peyriere H, Reynes J. 
Interactions between cytotoxic chemotherapy and antiretroviral 
treatment in human immunodeﬁ ciency virus-infected patients with 
lung cancer. J Thorac Oncol 2010; 5: 562–71.
Articles
www.thelancet.com/oncology   Vol 13   December 2012 1209
 24 Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient 
demographic and socioeconomic characteristics in the 
SEER-Medicare database applications and limitations. Med Care 
2002; 40 (8 suppl): IV-19–IV-25.
 25 Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview 
of the SEER-Medicare data: content, research applications, and 
generalizability to the United States elderly population. Med Care 
2002; 40 (8 suppl): IV-3–IV-18.
 26 Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell 
lung cancer with integrated positron-emission tomography and 
computed tomography. N Engl J Med 2003; 348: 2500–07.
 27 Rosenbaum PR, Rubin D. The central role of the propensity score 
in observational studies for causal eﬀ ects. Biometrika 1983; 
70: 41–55.
 28 D’Agostino R. Propensity score methods for bias reduction in the 
comparison of a treatment to a non-randomized control group. 
Stat Med 1998; 17: 2265–81.
 29 Rubin DB. Estimating causal eﬀ ects from large data sets using 
propensity scores. Ann Intern Med 1997; 127: 757–63.
 30 Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, 
Neugut AI. Survival associated with 5-ﬂ uorouracil-based adjuvant 
chemotherapy among elderly patients with node-positive colon 
cancer. Ann Intern Med 2002; 136: 349–57.
 31 Wong YN, Mitra N, Hudes G, et al. Survival associated with 
treatment vs observation of localized prostate cancer in elderly men. 
JAMA 2006; 296: 2683–93.
 32 Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. 
Treatment of non-small cell lung cancer stage I and stage II: ACCP 
evidence-based clinical practice guidelines (2nd edn). Chest 2007; 
132 (3 suppl): 234S–42S.
 33 Mountain CF, Dresler CM. Regional lymph node classiﬁ cation for 
lung cancer staging. Chest 1997; 111: 1718–23.
 34 Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients 
with human immunodeﬁ ciency virus infection. Cancer 2000; 
88: 563–69.
 35 Spina M, Sandri S, Serraino D, et al. Therapy of non-small-cell lung 
cancer (NSCLC) in patients with HIV infection. Ann Oncol 1999; 
10: 87–90.
 36 Bearz A, Vaccher E, Talamini R, Berretta M, Tirelli U. Comment on 
‘Lung cancer in the Swiss HIV Cohort Study: role of smoking, 
immunodeﬁ ciency and pulmonary infection’. Br J Cancer 2012; 
106: 1899–900.
 37 Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and 
costs of diagnostic imaging among Medicare beneﬁ ciaries with 
cancer, 1999–2006. JAMA 2010; 303: 1625–31.
 38 Dinan MA, Curtis LH, Carpenter WR, et al. Stage migration, 
selection bias, and survival associated with the adoption of positron 
emission tomography among medicare beneﬁ ciaries with 
non-small-cell lung cancer, 1998–2003. J Clin Oncol 2012; 
30: 2725–30.
 39 Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, 
Engels E. Disparities in the treatment and outcomes of lung cancer 
among HIV-infected individuals. AIDS 2012; published online 
Oct 17. DOI:10.1097/QAD.0b013e32835ad56e.
 40 Althoﬀ  KN, Buchacz K, Hall HI, et al. US trends in antiretroviral 
therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte 
cell counts among HIV-Infected persons, 2000 to 2008. 
Ann Intern Med 2012; 157: 325–35.
 41 Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents 
in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 
12: 905–12.
 42 Mitra N, Heitjan DF. Sensitivity of the hazard ratio to nonignorable 
treatment assignment in an observational study. Stat Med 2007; 
26: 1398–414.
 43 Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk 
factor for incident lung cancer. AIDS 2012; 26: 1017–25.
 44 Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning 
analysis of 1999 Radiation Therapy Oncology Group (RTOG) 
patients with locally-advanced non-small-cell lung cancer 
(LA-NSCLC): identiﬁ cation of ﬁ ve groups with diﬀ erent survival. 
Int J Radiat Oncol Biol Phys 2000; 48: 1475–82.
 45 May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 
infection starting antiretroviral therapy in sub-Saharan Africa: 
a collaborative analysis of scale-up programmes. Lancet 2010; 
376: 449–57.
